POM
POMDOCTOR Ltd
There isn't enough reported data to score POM yet.
POM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
POM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
POM PE Valuation
POM has no meaningful PE right now: it lost money over the past year.
POM Forward outlook
There aren't enough analyst estimates for POM to show an outlook.
POM Earnings Per Share
POM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $60M | +316% |
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30% | N/A |
| Q4 2024 | -8.8% | N/A |
POM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$22.4M | -$22M |
POM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -92% | -1.9M shares |
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
POM Net Leverage
POM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
POM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.4 | Oversold |
| Stochastic | 29.9 | Neutral |
POM's weekly RSI is 28 (oversold) and its Stochastic is 30 (neutral).
POM PE vs Healthcare Sector
POM has no meaningful PE right now: it lost money over the past year.
POM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.15 | 23% below |
| 20 week MA | $2.79 | 41% below |
| 50 week MA | $16.3 | 90% below |
POM is in a downtrend: it's below all three of its weekly moving averages, and 90% below its 50-week average.
POM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $261.0 | $21.2 | -92% |
| 2026 YTD | $21.2 | $1.66 | -92% |
POM has finished every year since 2025 lower, and it's down 92% so far in 2026.